Clinical trial
Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin…
NCT00110513 · rEVO Biologics, Industry · Completed
Key facts
| NCT number | NCT00110513 |
|---|---|
| Title | Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery |
| Official title | A Multicenter, Multinational Study to Assess the Safety and Efficacy of Antithrombin Alfa in Hereditary Antithrombin (AT) Deficient Patients in High-Risk Situations for Thrombosis |
| Lead sponsor | rEVO Biologics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Antithrombin III Deficiency |
| Intervention type | Biological |
| Interventions | Recombinant human antithrombin (rhAT) |
| Enrollment | 18 |
| Start date | Apr 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | May 11, 2005 |
| Last update posted | Aug 17, 2012 |
| Countries | Australia, Austria, Canada, France, Germany, Italy, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: